752
Views
39
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLEPreclinical Therapeutics

Low-Dose Metronomic Paclitaxel Chemotherapy Suppresses Breast Tumors and Metastases in Mice

, , , , &
Pages 74-84 | Published online: 09 Dec 2009
 

ABSTRACT

This study investigated the use of low-dose metronomic (LDM) chemotherapy with paclitaxel in a highly metastatic mouse model of 4T1 breast cancers, and compared it with the maximum tolerable dose (MTD) therapy. LDM therapy displayed a stronger anti-tumor activity in suppressing primary and metastatic breast tumors with less degree of side effects, and stronger anti-angiogenic and anti-lymphangiogenic activities than MTD therapy. But MTD therapy showed stronger pro-apoptotic and anti-proliferative activities in situ. Paclitaxel therapy downregulated expression of vascular endothelial growth factor receptor-2 (VEGFR2) and up-regulated expression of thrombospondin-1. The results support the application of paclitaxel LDM therapy to treat advanced breast cancer.

ACKNOWLEDGMENTS

The work was supported by the Ministry of Science and Technology, China (2007BAI07A05), the Science and Technology Bureau of Heilongjiang Province, China (WH05C02), the National Natural Scientific Foundation of China (30571808,30872987), and the Creative Foundation for Postgraduates in Heilongjiang Province, China (YJSCX2008-112HLJ to W Tao).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.